Navigating Disparities Amongst Treatment Guidelines: Management of Initial and Recurrent Clostridium difficile Infection – Module 3
Recognizing C. diff and its Burden in Diverse Healthcare Settings
Sponsored by the Academy for Continued Healthcare Learning.
This activity is supported by an independent education grant from Cubist Pharmaceuticals.
Scroll to the Bottom of this Information to Begin this Course
Release date: December 9, 2014
Valid through: December 9, 2015
Specialty: Gastroenterology, Infectious disease
Topic: Clostridium difficile Infection
Estimated Time to Complete Activity: 30 minutes
This educational activity is designed for gastroenterologists and other healthcare professionals treating Clostridium difficile infections.
The epidemiology and incidence of hospital- and community-acquired CDI have changed over the past decade. As such, clinicians must be familiar with evolving diagnostic parameters, guidelines, and treatment approaches to reduce complications and improve clinical outcomes.
Upon completion of this activity, participants should be better able to:
- Discuss the diagnosis of C. diff infection and assessment of disease severity
- Compare and contrast clinical outcomes with pharmacotherapies for C. diff infection
- Physicians — maximum of 0.5 AMA PRA Category 1 Credit(s)™
All other health care professionals completing this course will be issued a statement of participation.
Darrell S. Pardi, MD (Chair)
Professor of Medicine
Inflammatory Bowel Disease Clinic
Division of Gastroenterology and Hepatology
Mayo Clinic College of Medicine
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures of Conflicts of Interest
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. ACHL also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.
The following financial relationships have been provided:
Darrell S. Pardi, MD (Chair)
- Advisory Panel: Cubist Pharmaceuticals
Staff and Reviewer Disclosures
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
Instructions for Participation and Credit
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online webcast and complete the post-test and evaluation form. To receive credit, 65% must be achieved on the post-test. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Hardware and Software Requirements
This site is best viewed with an HTML5 compatible browser, this list includes the versions of Mircrosoft Internet Explorer, Mozilla Firefox, Google Chrome, and Apple's Safari. You can visit the independent (3rd party) site www.whatismybrowser.com to determine if you have the latest version of your browser. Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. This activity requires: Adobe Flash Player
Disclosure of Unlabeled Use
Discussion of off-label, investigational, or experimental drug/device use: Use of metronidazole, intravenous immunoglobulin, rifaximin, tigecycline, and linezolid for treatment of C. diff infections.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Inquires may be directed to ACHL at (877) 444-8435, ext. 203.